Founded in 2013, VESALIO™ is a privately held medical device company focused on advancing technology needed to improve outcomes in stroke treatment.

 

The Company’s proprietary NeVa™ platform is designed to achieve superior, safe and repeatable clinical outcomes by providing physicians improved first pass success in effectively removing the entire spectrum of clot from neurovascular anatomy.

WHY IS VESALIO DRIVEN TO ADVANCE STROKE TREATMENT?

Ischemic Stroke is a devastating acute condition with a high risk of loss of life or neurological function. It is an emergency condition, where death rapidly spreads through brain tissue and every minute is crucial.
 

Today, thanks to highly trained neuro-endovascular interventionalists, saving patients once considered untreatable is possible. Stroke teams race against time to treat patients by capturing and removing the clots that block blood flow in the brain. 


Current clot removing technologies have crossed the chasm into mainstream therapeutic use, launching a new standard of care. However, today's most commonly employed devices were adapted from technologies used for other indications, and are not specifically optimized for removing all neurovascular clots.


Clots come in different sizes and consistency. Studies have shown that when it comes to the more organized, fibrin-rich, hard or calcified varieties, conventional neuro-thrombectomy devices require multiple passes or fail completely.

NeVa™ is designed 1st Pass Success with ALL clot types taking clot capture to the next level with Drop Zone™ Technology

IMPROVE STROKE OUTCOMES. DO THE DROP ZONE.

Contact Us

Vesalio_CircleLogo_White.png
  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon

NeVa T, M1, M1-S and VS are CE-Marked

Caution - Investigational Device Limited by Federal Law

to Investigational Use.

150x132_graphic_logo_web.gif